Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2009 Apr;24(2):242-7.
doi: 10.3346/jkms.2009.24.2.242. Epub 2009 Apr 20.

The efficacy of hepatic resection after neoadjuvant transarterial chemoembolization (TACE) and radiation therapy in hepatocellular carcinoma greater than 5 cm in size

Affiliations
Case Reports

The efficacy of hepatic resection after neoadjuvant transarterial chemoembolization (TACE) and radiation therapy in hepatocellular carcinoma greater than 5 cm in size

Sae Byeol Choi et al. J Korean Med Sci. 2009 Apr.

Abstract

In cases of large hepatocellular carcinoma (HCC), neoadjuvant treatment such as transarterial chemoembolization (TACE) and radiation therapy can be performed. The aim of this study was to evaluate the outcome of these treatments prior to hepatic resection. Between January 1994 and May 2007, 16 patients with HCC greater than 5 cm in size were treated with TACE and radiation therapy prior to hepatic resection. The clinicopathologic factors were reviewed retrospectively. Of the 16 patients, there were 14 men and two women, and the median age was 52.5 yr. TACE was performed three times in average, and the median radiation dosage was 45 Gy. The median diameter of tumor on specimen was 9.0 cm. The degree of tumor necrosis was more than 90% in 14 patients. The median survival time was 13.3 months. Five patients had survived more than 2 yr and there were two patients who had survived more than 5 yr. Although the prognosis of large HCC treated with neoadjuvant therapy is not satisfactory, some showed long-term survival loger than 5 yr. Further research will be required to examine the survival and disease control effect in a prospective randomized study.

Keywords: Carcinoma, Hepatocellular; Hepatic Resection; Radiotherapy; TACE.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overall survival curve of the 16 patients.

Similar articles

Cited by

References

    1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: globocan 2000. Int J Cancer. 2001;94:153–156. - PubMed
    1. Annual report on the cause of death statistics. Korean statistical information system. Available at: http://kosis.kr.
    1. Makuuchi M, Takayama T, Kubota K, Kimura W, Midorikawa Y, Miyagawa S, Kawasaki S. Hepatic resection for hepatocellular carcinoma--Japanese experience. Hepatogastroenterology. 1998;45:1267–1274. - PubMed
    1. Tsuzuki T, Sugioka A, Ueda M, Iida S, Kanai T, Yoshii H, Nakayasu K. Hepatic resection for hepatocellular carcinoma. Surgery. 1990;107:511–520. - PubMed
    1. Kim SS, Lee CD, Choi SW, Han NI, Kim JI, Han SW, Yoon SK, Yang JM, Park YM, Han SW, Lee YS, Park DH, Kim BS. Prognosis and prognostic factors in patients with hepatocellular carcinoma treated by transarterial chemoembolization. Korean J Gastroenterol. 1997;30:72–80.

Publication types

MeSH terms